Literature DB >> 11082322

Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy.

J A Howe1, G W Demers, D E Johnson, S E Neugebauer, S T Perry, M T Vaillancourt, B Faha.   

Abstract

The oncolytic effect of adenoviruses may provide an efficient means to destroy tumor tissue if viruses could be developed with sufficient selectivity and efficacy. In this report we have characterized several adenoviruses, each with different mutations in the E1 region, for selective cytopathic effect in tumor cells in vitro and for their ability to inhibit tumor growth in vivo. Of the E1 mutants tested, we have identified one, E1Adl01/07, which preferentially induces cytopathic effects in a range of tumor cells versus primary cells. In addition, E1Adl01/07 significantly inhibited tumor growth and increased survival of mice in several models of human cancer. These results suggest that E1Adl01/07 might serve as an effective cancer therapeutic, combining both selectivity and efficacy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11082322     DOI: 10.1006/mthe.2000.0206

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  10 in total

Review 1.  Intrinsic structural disorder in adenovirus E1A: a viral molecular hub linking multiple diverse processes.

Authors:  Peter Pelka; Jailal N G Ablack; Gregory J Fonseca; Ahmed F Yousef; Joe S Mymryk
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

Review 2.  Current issues and future directions of oncolytic adenoviruses.

Authors:  Masato Yamamoto; David T Curiel
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

3.  Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas.

Authors:  Hong Jiang; Candelaria Gomez-Manzano; Ramon Alemany; Diana Medrano; Marta Alonso; B Nebiyou Bekele; E Lin; Charles C Conrad; W K Alfred Yung; Juan Fueyo
Journal:  Neoplasia       Date:  2005-01       Impact factor: 5.715

4.  Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model.

Authors:  Zhenwei Zhang; Jeffrey Krimmel; Zhiling Zhang; Zebin Hu; Prem Seth
Journal:  Hum Gene Ther       Date:  2011-06-08       Impact factor: 5.695

5.  Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer.

Authors:  Zebin Hu; Helen Gerseny; Zhenwei Zhang; Yun-Ju Chen; Arthur Berg; Zhiling Zhang; Stuart Stock; Prem Seth
Journal:  Mol Ther       Date:  2011-06-28       Impact factor: 11.454

6.  Future directions and treatment strategies for head and neck squamous cell carcinomas.

Authors:  Trisha M Wise-Draper; David J Draper; J Silvio Gutkind; Alfredo A Molinolo; Kathryn A Wikenheiser-Brokamp; Susanne I Wells
Journal:  Transl Res       Date:  2012-02-28       Impact factor: 7.012

7.  Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model.

Authors:  Zebin Hu; Janhavi Gupta; Zhenwei Zhang; Helen Gerseny; Arthur Berg; Yun Ju Chen; Zhiling Zhang; Hongyan Du; Charles B Brendler; Xianghui Xiao; Kenneth J Pienta; Theresa Guise; Chung Lee; Paula H Stern; Stuart Stock; Prem Seth
Journal:  Hum Gene Ther       Date:  2012-06-25       Impact factor: 5.695

8.  Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model.

Authors:  Zebin Hu; Zhenwei Zhang; Theresa Guise; Prem Seth
Journal:  Hum Gene Ther       Date:  2010-09-09       Impact factor: 5.695

9.  Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro.

Authors:  Li Wang; Yunxin Zhang; Jinxia Zhao; Erlong Xiao; Jianzhong Lu; Shengjun Fu; Zhiping Wang
Journal:  Tumour Biol       Date:  2014-08-02

10.  Developing novel oncolytic adenoviruses through bioselection.

Authors:  Wen Yan; Galila Kitzes; Farid Dormishian; Lynda Hawkins; Adam Sampson-Johannes; Josh Watanabe; Jenny Holt; Vivian Lee; Thomas Dubensky; Ali Fattaey; Terry Hermiston; Allan Balmain; Yuqiao Shen
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.